Changes in surgical strategy, cytoreductive outcomes, and survival patterns in advanced ovarian cancer before and after the introduction of poly(ADP-ribose) polymerase inhibitors: an integrated analysis of the GOTIC-019 and GOTIC-033 cohorts
Background We examined changes in surgical strategy, cytoreductive outcomes, and survival patterns after PARP inhibitors became available for first-line maintenance therapy in Japan. Methods We integrated two multicenter retrospective cohorts: GOTIC-019 before PARP inhibitor introduction (n = 988) and GOTIC-033 afterward (n = 663). Treatment strategy, cytoreductive outcomes, and Kaplan–Meier estimates were summarized descriptively without formal between-era survival testing. Results The primary debulking surgery (PDS)-attempt cohort decreased from 50.7% to 36.1%, whereas exploratory surgery increased from 9.5% to 25.6%. Complete cytoreduction accounted for 35.1% and 40.4% of PDS procedures and 61.7% and 61.5% of interval debulking surgery (IDS) before and after PARP inhibitor introduction, respectively. In patients who had initiated PARP inhibitors, 353 out of 663 (53.2%) were receiving PARP inhibitor maintenance therapy. Median progression-free survival (PFS) was 22 and 43 months in the PDS-attempt cohorts and 19 and 22 months in the neoadjuvant chemotherapy (NAC)–IDS-attempt cohorts. After complete, optimal, and suboptimal PDS, median PFS was 100, 19, and 17 months before PARP inhibitor introduction and not reached, 32, and 25 months afterward. After complete, optimal, and suboptimal IDS, median PFS was 23, 17, and 15 months before PARP inhibitor introduction and 32, 23, and 13 months afterward. Conclusion Complete cytoreduction appeared to confer a survival benefit; however, findings regarding overall survival should be interpreted with caution due to the limited follow-up duration. PDS should be prioritized when complete cytoreduction is feasible with acceptable morbidity; otherwise, neoadjuvant chemotherapy–IDS should pursue complete cytoreduction.
Authors
- Kohei Tamura (ORCID: https://orcid.org/0000-0001-5957-930X)
- Hiroya Itagaki (ORCID: https://orcid.org/0000-0001-9622-0611)
- Keiichi Fujiwara (ORCID: https://orcid.org/0000-0002-7388-0243)
- Takashi Shibutani
- Hisashi Masuyama (ORCID: https://orcid.org/0000-0003-2589-2028)
- Takashi Hirakawa (ORCID: https://orcid.org/0009-0009-1080-8680)
- Shoji Nagao (ORCID: https://orcid.org/0000-0003-4031-8091)
- Naoyuki Ida (ORCID: https://orcid.org/0009-0000-5697-606X)
- Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1903-7001)
- Yuichi Imai (ORCID: https://orcid.org/0000-0001-7347-9719)
- Mitsuya Ishikawa (ORCID: https://orcid.org/0000-0001-8855-2966)
- Kouji Yamamoto (ORCID: https://orcid.org/0000-0003-0696-9659)
- Soichi Yamashita (ORCID: https://orcid.org/0009-0003-9454-4526)
- Takashi Matsumoto
Institutions
- University of Tsukuba (JP)
- Jichi Medical University (JP)
- Okayama University (JP)
- Gunma University (JP)
- Hyogo Prefectural Cancer Center (JP)
- Ehime University (JP)
- Gunma Prefectural Cancer Center (JP)
- Saitama Medical University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-10487182/v1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- preprint